Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.
about
Type I interferons for induction of remission in ulcerative colitisType I interferons for induction of remission in ulcerative colitisImmunomodulatory functions of type I interferonsInfluenza Virus Affects Intestinal Microbiota and Secondary Salmonella Infection in the Gut through Type I InterferonsTwist mediates suppression of inflammation by type I IFNs and AxlInterferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding studyToll-like receptor 9-induced type I IFN protects mice from experimental colitis.STAT2 contributes to promotion of colorectal and skin carcinogenesis.Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitisType I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity.Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-α/β reduction.Novel biological strategies in inflammatory bowel diseases.Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.The role of type I interferons in intestinal infection, homeostasis, and inflammation.Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis.Lessons from type I interferons in ulcerative colitis.Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production.Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitisInterfering with interferons in inflammatory bowel disease.Treatment of inflammatory bowel disease: a review of medical therapy.Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice.Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.Investigational cytokine-targeted therapies for ulcerative colitis.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.Type 1 Interferon in the Human Intestine-A Co-ordinator of the Immune Response to the Microbiota.Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology.Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNAPlasmacytoid dendritic cell-derived IFNα modulates Th17 differentiation during early Bordetella pertussis infection in mice.Illuminating the role of type I IFNs in colitis.Practical guidelines for the treatment of inflammatory bowel disease.Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
P2860
Q24187202-7EEBCC0E-363F-4458-9A9B-F6D848A60ED6Q24241993-C4962B2D-2604-45CF-87DB-15AD5421B230Q26823904-434E7FD0-F7AC-4C1E-AC37-D32484D6D233Q27314790-74A74755-AE88-4CF5-B50C-40304835BE8FQ28509359-7EC5E411-C872-4A4A-805E-FF53A7CDAB20Q33420096-0D31A671-BB12-4AAC-9CA2-D0EFD7574A7AQ33683729-C0A47396-CFE0-4A87-AB05-8D2C6664B826Q33776485-76F398B3-E9E4-42FA-BD13-03A5DE40911BQ34050559-0800DA03-0FD1-45D5-A20B-D68F6DB3C467Q34164176-ECA8E5F3-4732-437A-A03A-ABCCA4AB11F6Q34609698-EB329E46-1BB9-421A-B7FF-BCEE142019E1Q35787653-84AB11BE-2069-4389-84D1-580D3C1EA5D6Q35889006-02D95B47-68A0-4B15-B180-CC61FE7B1472Q36001052-096B48CB-331F-4647-9BE2-780748AC5881Q36045739-42B168FF-3140-4313-AC3B-ED16C2FA61C5Q36116972-935E1A0C-AE9A-4C3F-8A01-816A742EB413Q36199597-1B177AB8-F998-4590-B25E-E20C7F71B018Q36302922-A0208D14-49E3-478D-B03E-93AECE6ED1DFQ36540026-1DC9E410-151E-4415-9B66-2056119007F4Q37058862-D0440E2A-92F3-45C6-B696-8DD8CFFA3996Q37059745-A57578D1-345C-4AD2-92B4-DA56CB85D2D7Q37957968-0F4B61EF-9CA5-407C-AD00-2220CD1FA78BQ38004932-045D1C11-E53D-4A04-9562-A8367602C2B5Q38117175-D64338F3-9A7E-4448-85C7-F7947D93E4C1Q38132555-E7C9CB60-231B-46E8-8CD6-ECDB7A8949E8Q38744710-37BCBE77-1F77-456B-BED9-750D0D053125Q39205799-DBFD3ABE-4FF1-46A5-8695-B2A70588712FQ39835471-6CC5E936-8774-4C58-82CD-657C5E169AF4Q40954945-4B1A6CA8-F587-436C-9C1B-4857E6407890Q41901994-D352FC58-8AEC-455D-9677-0B2394024DA8Q42846582-84F30F79-5462-4786-8EC1-B866C8156F2AQ43004582-D6A35008-CFB5-4A59-9475-0A0D6F850EF8Q47958039-83175B2D-B62C-4F9E-A3F0-E99A9A70F77C
P2860
Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@ast
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@en
type
label
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@ast
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@en
prefLabel
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@ast
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@en
P2093
P2860
P356
P1433
P1476
Interferon beta-1a in ulcerati ...... omised, dose escalating study.
@en
P2093
A H Steinhart
P Rutgeerts
S Nikolaus
S Schreiber
P2860
P304
P356
10.1136/GUT.52.9.1286
P407
P577
2003-09-01T00:00:00Z